Chemotherapy in the Covid-19 era: the patient's perception.
Cancer
Chemotherapy
Covid-19 pandemic
Psychosocial impact
Journal
Irish journal of medical science
ISSN: 1863-4362
Titre abrégé: Ir J Med Sci
Pays: Ireland
ID NLM: 7806864
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
11
10
2020
accepted:
03
12
2020
pubmed:
16
1
2021
medline:
21
10
2021
entrez:
15
1
2021
Statut:
ppublish
Résumé
The Covid-19 pandemic poses significant challenges for the management of patients with cancer. In our institution, we adapted our delivery of outpatient systemic anti-cancer therapy (SACT) by introducing a number of 'risk-reducing' measures including pre-assessment screening. We sought to evaluate the experience and perceptions of patients with cancer undergoing SACT during the Covid-19 pandemic. Patients on SACT during the Covid-19 pandemic were eligible for participation. Data were collected by anonymous survey over a 1 week period during the most intensive phase of government restrictions. Patients were asked questions under three headings: perceived risk of infection exposure, changes to treatment plan and psychological impact of Covid-19. One hundred patients were assessed, 60% were male, 41% were > 65 years of age and 67% had advanced cancer. Eleven percent of patients were living alone. Fifty-seven percent reported feeling at increased risk in general of contracting Covid-19. Sixty-eight percent of patients did not feel worried about contracting Covid-19 in the hospital. Ninety-two percent of patients reported wanting to continue on SACT as originally planned. Fifty-eighty percent felt isolated and 40% reported increased anxiety. Though patients on active treatment for cancer during the Covid-19 pandemic reported increased anxiety and feelings of isolation due to Covid-19, the majority of patients wanted to continue SACT as originally planned. Patients would benefit from enhanced psycho-oncological supports in the event of a prolonged Covid-19 pandemic.
Sections du résumé
BACKGROUND
BACKGROUND
The Covid-19 pandemic poses significant challenges for the management of patients with cancer. In our institution, we adapted our delivery of outpatient systemic anti-cancer therapy (SACT) by introducing a number of 'risk-reducing' measures including pre-assessment screening.
AIMS
OBJECTIVE
We sought to evaluate the experience and perceptions of patients with cancer undergoing SACT during the Covid-19 pandemic.
METHODS
METHODS
Patients on SACT during the Covid-19 pandemic were eligible for participation. Data were collected by anonymous survey over a 1 week period during the most intensive phase of government restrictions. Patients were asked questions under three headings: perceived risk of infection exposure, changes to treatment plan and psychological impact of Covid-19.
RESULTS
RESULTS
One hundred patients were assessed, 60% were male, 41% were > 65 years of age and 67% had advanced cancer. Eleven percent of patients were living alone. Fifty-seven percent reported feeling at increased risk in general of contracting Covid-19. Sixty-eight percent of patients did not feel worried about contracting Covid-19 in the hospital. Ninety-two percent of patients reported wanting to continue on SACT as originally planned. Fifty-eighty percent felt isolated and 40% reported increased anxiety.
CONCLUSION
CONCLUSIONS
Though patients on active treatment for cancer during the Covid-19 pandemic reported increased anxiety and feelings of isolation due to Covid-19, the majority of patients wanted to continue SACT as originally planned. Patients would benefit from enhanced psycho-oncological supports in the event of a prolonged Covid-19 pandemic.
Identifiants
pubmed: 33449325
doi: 10.1007/s11845-020-02457-3
pii: 10.1007/s11845-020-02457-3
pmc: PMC7809239
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1303-1308Informations de copyright
© 2021. Royal Academy of Medicine in Ireland.
Références
JAMA Intern Med. 2020 Jun 1;180(6):817-818
pubmed: 32275292
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Lancet. 2019 Jun 29;393(10191):2599-2612
pubmed: 31178152
Lancet Psychiatry. 2020 Jun;7(6):547-560
pubmed: 32304649
Asia Pac J Clin Oncol. 2018 Apr;14(2):e181-e192
pubmed: 28371441
JCO Glob Oncol. 2020 Sep;6:1461-1471
pubmed: 32997537
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Lancet. 2020 Mar 14;395(10227):912-920
pubmed: 32112714
JCO Oncol Pract. 2020 Jun;16(6):305-307
pubmed: 32324487
Asian J Psychiatr. 2020 Jun;51:102092
pubmed: 32315963
Ann Oncol. 2020 Oct;31(10):1320-1335
pubmed: 32745693
Psychiatry Clin Neurosci. 1999 Oct;53(5):569-73
pubmed: 10595681
Ann Oncol. 2018 Dec 1;29(12):2328-2333
pubmed: 30219886
Cancer Invest. 2016;34(2):94-104
pubmed: 26864862
Eur J Cancer. 2020 Sep;136:132-139
pubmed: 32683273
Breast J. 2020 Aug;26(8):1597-1602
pubmed: 32677117
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
Nat Rev Clin Oncol. 2020 May;17(5):268-270
pubmed: 32242095